June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
TNFa and other Select Cytokines in Patients with Intermediate Age-Related Macular Degeneration (iAMD)
Author Affiliations & Notes
  • Maryam Ghiassi
    Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Brandie D. Wagner
    Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Alan Palestine
    Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Naresh Mandava
    Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Anne M. Lynch
    Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
  • Footnotes
    Commercial Relationships   Maryam Ghiassi None; Brandie Wagner None; Alan Palestine None; Naresh Mandava None; Anne Lynch None
  • Footnotes
    Support  Research supported in this publication was supported by the National Eye Institute of the National Institutes of Health under award number R01EY032456 (AML), a Research to Prevent Blindness grant to the Department of Ophthalmology, University of Colorado, the Frederic C. Hamilton Macular Degeneration Center, Sue Anschutz-Rogers Eye Center Research Fund, and by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 355 – F0186. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maryam Ghiassi, Brandie D. Wagner, Alan Palestine, Naresh Mandava, Anne M. Lynch; TNFa and other Select Cytokines in Patients with Intermediate Age-Related Macular Degeneration (iAMD). Invest. Ophthalmol. Vis. Sci. 2022;63(7):355 – F0186.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age related macular degeneration (AMD) is a leading cause of blindness worldwide. The disease affects the local microenvironment of photoreceptors and retinal pigment epithelium causing an irreversible cell loss and subsequent decline in vision. It has been shown by our group that patients with iAMD have significantly altered levels of several inflammatory biomarkers, including complement factors and CCLx chemokines, in cases with iAMD compared to control patients without AMD. Building on this research that supports a role for systemic inflammation in patients with iAMD, we embarked on this study to compare levels of plasma cytokines namely, TNFa, IL-6. IL-8, IL-1ra, IL-4, and VEGF in patients with iAMD compared to controls with no AMD.

Methods : Patients with iAMD who were part of the University of Colorado IRB approved AMD registry were included in this study. Imaging studies and blood plasma samples were obtained from both iAMD and control patients. Cases and controls were defined using the Beckmann classification and multimodal imaging. The cytokine analysis was conducted using current established laboratory protocols. Wilcoxon rank-based tests were used to compare cytokine levels between the two groups.

Results : There were 211 patients with iAMD and 100 controls. The iAMD and control groups were comparable in smoking status, BMI, hypertension, cardiac and vascular disease. We found TNFa levels to be significantly higher in cases with iAMD compared to control patients (P<0.01). Levels of IL-6, IL-8, IL-1ra, IL-4 and VEGF levels did not differ between cases and controls (Table-1).

Conclusions : Patients with iAMD had higher levels of TNFa, a key regulator of the inflammatory response, compared with controls. TNFa is produced by macrophages, monocytes and other cells and has been shown to have direct effects on retinal pigment epithelial cells including induction of complement expression and up-regulation of VEGF production. These findings support our hypothesis that systemic inflammatory markers can distinguish patients with and without iAMD. Serum TNFa levels can potentially be used as a biomarker to identify high risk patients with iAMD.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×